Medical School · Year 2 · Endocrine · includes a quiz and discussion video

Lecture 10: Calcium and Bone Metabolism

Unit 2.3: Endocrine System

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe calcium homeostasis and distribution in the body
2. Explain the synthesis and actions of parathyroid hormone (PTH)
3. Describe vitamin D metabolism and functions
4. Explain the role of calcitonin and other calcium-regulating factors
5. Describe bone physiology and remodeling
6. Explain the integrated hormonal regulation of calcium and phosphorus

Lecture Outline

I. Calcium Homeostasis - Overview

Calcium is one of the most tightly regulated ions in the body, and understanding its distribution across compartments is essential for interpreting clinical disorders. The total body calcium content is approximately 1000-1200 g, with the vast majority residing in bone. Bone serves as the body's calcium reservoir, containing approximately 1000 g, which accounts for 99% of total body calcium stored primarily as hydroxyapatite crystals. The intracellular compartment holds approximately 10 g, representing roughly 1% of total body calcium, while the extracellular fluid contains only about 1 g, a mere 0.1% of the total. Despite its small proportion, the extracellular calcium concentration is critical for numerous physiologic processes including neuromuscular function, coagulation, and cell signaling.

Plasma calcium exists in three distinct forms, and understanding this partitioning is essential for accurate clinical assessment. Ionized (free) calcium accounts for 50% of total plasma calcium and is the biologically active fraction responsible for physiologic effects. Protein-bound calcium constitutes approximately 40% of the total, with albumin being the principal binding protein. The remaining 10% circulates as complexed calcium, bound to anions such as phosphate and citrate. The normal total serum calcium concentration is 8.5-10.5 mg/dL (2.1-2.6 mmol/L), but because only the ionized fraction is physiologically active, conditions that alter protein binding can create discrepancies between total calcium measurements and the true biologically relevant calcium level.

The albumin correction for calcium is a clinically indispensable calculation, particularly in hospitalized patients who frequently have hypoalbuminemia. Because approximately 40% of plasma calcium is bound to albumin, a decrease in serum albumin causes total calcium to appear falsely low even when the ionized fraction remains normal. The correction formula accounts for this relationship: for each 1 g/dL decrease in albumin below the normal value of 4 g/dL, the total calcium appears approximately 0.8 mg/dL lower than the true value. The corrected calcium is therefore calculated as measured calcium plus 0.8 multiplied by the difference between 4 and the measured albumin level. As an alternative that avoids this estimation entirely, ionized calcium can be measured directly, which provides the most accurate assessment of the biologically active fraction and is particularly useful in critically ill patients.

The effect of blood pH on ionized calcium has important clinical implications, particularly in acute settings. In acidosis, hydrogen ions compete with calcium for binding sites on albumin, displacing calcium and increasing the ionized fraction. Conversely, in alkalosis, fewer hydrogen ions compete for albumin binding sites, allowing more calcium to bind to albumin and thereby decreasing the ionized fraction. This relationship explains why hyperventilation, which causes respiratory alkalosis, can precipitate symptoms of hypocalcemia including tetany and paresthesias even when total calcium levels are normal. The classic clinical scenario is a patient hyperventilating from anxiety who develops carpopedal spasm due to the acute reduction in ionized calcium caused by the rise in blood pH.

<image>Panel A: Body calcium distribution showing 99% in bone (approximately 1000 g), 1% intracellular, and 0.1% extracellular in a proportional diagram. Panel B: Plasma calcium forms as pie chart with ionized/free (50%, biologically active), protein-bound (40%, mainly albumin), and complexed (10%, phosphate and citrate). Panel C: Albumin correction formula showing corrected calcium equals measured calcium plus 0.8 times (4 minus albumin), with clinical example of hypoalbuminemia causing falsely low total calcium. Panel D: pH effects on ionized calcium showing acidosis increasing ionized calcium (hydrogen ions displacing calcium from albumin) and alkalosis decreasing ionized calcium (more binding to albumin), with hyperventilation-induced tetany as clinical example.</image>

II. Calcium Functions

Calcium plays essential roles in virtually every organ system, functioning both as a structural element and as a critical signaling molecule. In bone, calcium in the form of hydroxyapatite provides the mineral rigidity that gives the skeleton its structural integrity. In muscle tissue, calcium is the key trigger for contraction, binding to troponin C and initiating the cross-bridge cycling between actin and myosin that generates force. In the nervous system, calcium is essential for both the generation of action potentials and the release of neurotransmitters at synaptic terminals, where calcium influx through voltage-gated channels triggers vesicle fusion with the presynaptic membrane. Calcium also serves as a critical cofactor in the coagulation cascade, participating in the activation of multiple clotting factors. At the intracellular level, calcium functions as a ubiquitous second messenger, mediating signal transduction through pathways involving calmodulin and protein kinase C. Additionally, calcium is required for exocytosis, the process by which secretory vesicles release their contents into the extracellular space.

The neuromuscular effects of calcium are among the most clinically relevant manifestations of calcium disorders. Hypocalcemia increases neuromuscular excitability by lowering the threshold for nerve and muscle fiber depolarization, which can progress to tetany, characterized by involuntary muscle contractions, carpopedal spasm, and in severe cases laryngospasm. The clinical signs of Chvostek (facial muscle twitching upon tapping the facial nerve) and Trousseau (carpal spasm with blood pressure cuff inflation) reflect this heightened excitability. Conversely, hypercalcemia decreases neuromuscular excitability by raising the depolarization threshold, resulting in muscle weakness, hyporeflexia, and in severe cases flaccid paralysis. These opposing effects underscore why the body maintains ionized calcium within such a narrow range.

The daily calcium balance reflects the interplay between intestinal absorption, renal excretion, and bone turnover. The recommended dietary calcium intake is 800-1200 mg per day, though only approximately 30% of ingested calcium is absorbed in the intestine, yielding a net absorption of roughly 300 mg. Intestinal calcium absorption occurs primarily in the duodenum and is heavily regulated by vitamin D. On the excretion side, the kidneys eliminate approximately 200 mg of calcium per day, while fecal losses account for unabsorbed dietary calcium plus calcium secreted into the gastrointestinal tract. In the steady state, net calcium balance is zero, meaning that the amount absorbed from the gut equals the amount lost through renal and fecal excretion. When this balance is disrupted, as in vitamin D deficiency or chronic kidney disease, the body compensates by mobilizing calcium from its vast skeletal reservoir through increased bone resorption.

<image>Panel A: Calcium in bone showing hydroxyapatite crystal structure as the structural mineral component providing skeletal rigidity and serving as the body's calcium reservoir. Panel B: Calcium roles in muscle contraction (troponin binding triggering actin-myosin interaction) and nerve function (action potential generation and neurotransmitter release at synaptic terminals). Panel C: Additional calcium functions including coagulation cascade factor activation, intracellular second messenger signaling, and exocytosis of secretory vesicles. Panel D: Daily calcium balance diagram showing dietary intake (800-1200 mg/day recommended), intestinal absorption (approximately 30%, 300 mg), renal excretion (200 mg/day), and fecal loss with net zero balance in steady state.</image>

III. Parathyroid Hormone (PTH)

The parathyroid glands are the principal regulators of calcium homeostasis, and their anatomy reflects their critical endocrine function. There are usually four parathyroid glands, though the number can range from three to six due to developmental variation. They are located on the posterior surface of the thyroid gland, each weighing approximately 30-50 mg. Embryologically, the superior parathyroid glands derive from the fourth pharyngeal pouch, while the inferior glands derive from the third pharyngeal pouch, migrating caudally alongside the thymus during development. This migratory pathway explains why ectopic parathyroid tissue can be found anywhere from the angle of the mandible to the mediastinum. The parathyroid glands contain two principal cell types: chief cells, which are the primary PTH-producing cells, and oxyphil cells, whose function remains less well understood but which increase in number with age.

PTH is synthesized as a precursor molecule that undergoes sequential processing before secretion. The mature hormone is an 84 amino acid polypeptide, but it is initially translated as pre-pro-PTH, which is then cleaved to pro-PTH and finally to the mature PTH molecule within the secretory pathway. The biologic activity of PTH resides in the N-terminal 1-34 amino acid fragment, a finding exploited therapeutically with the development of teriparatide (recombinant PTH 1-34) for osteoporosis treatment. Once secreted, PTH has a remarkably short plasma half-life of approximately 4 minutes, reflecting rapid hepatic and renal clearance. PTH secretion occurs in a pulsatile fashion, and it is the minute-to-minute regulation of secretion rate rather than changes in synthesis that provides the fine-tuned control of serum calcium.

The regulation of PTH secretion involves multiple inputs, with ionized calcium serving as the dominant controller. Low ionized calcium is the primary stimulus for PTH release, while elevated ionized calcium suppresses it. Vitamin D also modulates PTH: low vitamin D levels stimulate PTH secretion (contributing to secondary hyperparathyroidism in vitamin D deficiency), while high vitamin D levels suppress PTH through direct transcriptional repression. The relationship between magnesium and PTH is particularly nuanced and clinically important. Mild to moderate hypomagnesemia impairs the secretory machinery of the parathyroid gland, paradoxically decreasing PTH release despite concurrent hypocalcemia. This explains why hypocalcemia may be refractory to calcium replacement until magnesium deficiency is corrected. In contrast, very low magnesium levels can themselves cause hypocalcemia, which then stimulates PTH release through the usual calcium-sensing mechanism.

The calcium-sensing receptor (CaSR) is the molecular sensor that mediates the parathyroid gland's response to circulating calcium. It is a G protein-coupled receptor located on the surface of parathyroid chief cells and also expressed in renal tubular cells. The CaSR directly senses ionized calcium in the extracellular fluid: when calcium is high, CaSR is activated, triggering intracellular signaling cascades that suppress PTH secretion. When calcium is low, CaSR is inactive, removing the tonic inhibition on PTH release and allowing secretion to increase. Mutations in the CaSR gene cause two clinically distinct disorders. Inactivating mutations cause familial hypocalciuric hypercalcemia (FHH), in which the set point for calcium sensing is shifted upward, resulting in mild hypercalcemia with inappropriately low urinary calcium excretion. Activating mutations cause autosomal dominant hypocalcemia (ADH), in which the receptor is overly sensitive to calcium, suppressing PTH at inappropriately low calcium levels and causing hypocalcemia with relative hypercalciuria.

<image>Panel A: Parathyroid gland anatomy showing four glands on the posterior thyroid surface, each weighing 30-50 mg, with chief cells producing PTH and embryologic origin from the third and fourth pharyngeal pouches. Panel B: PTH structure as 84 amino acid polypeptide with active N-terminal 1-34 fragment highlighted, processing from pre-pro-PTH through pro-PTH to mature PTH, and 4-minute plasma half-life. Panel C: PTH secretion regulation table showing low ionized calcium as primary stimulus for increased PTH, high calcium suppressing PTH, and paradoxical effect of magnesium (low Mg impairs PTH secretion). Panel D: Calcium-sensing receptor (CaSR) mechanism on parathyroid chief cells showing G protein-coupled receptor activation by high calcium (suppressing PTH) and inactivation by low calcium (increasing PTH), with mutations causing FHH (inactivating) and ADH (activating).</image>

IV. PTH Actions

The overall effects of PTH on mineral metabolism can be summarized by its net impact on serum and urine concentrations of calcium and phosphorus. PTH raises serum calcium and lowers serum phosphorus, a reciprocal pattern that prevents the calcium-phosphorus product from rising to levels that would promote ectopic calcification. In the urine, PTH increases both calcium and phosphorus excretion. The increase in urinary phosphorus is a direct effect of PTH inhibiting phosphate reabsorption in the proximal tubule. The increase in urinary calcium may seem paradoxical given that PTH simultaneously enhances calcium reabsorption in the distal tubule, but the net increase in urinary calcium results from the increased filtered load of calcium caused by PTH-driven bone resorption and intestinal absorption, which overwhelms the enhanced distal reabsorption.

The bone effects of PTH represent one of the most rapidly acting mechanisms for raising serum calcium. PTH stimulates bone resorption, thereby releasing calcium and phosphorus from the skeletal reservoir into the circulation. Importantly, PTH does not act directly on osteoclasts, as osteoclasts lack PTH receptors. Instead, PTH acts on osteoblasts, which then signal to osteoclast precursors through the RANK/RANKL/OPG system. Specifically, PTH increases the expression of RANKL (receptor activator of nuclear factor kappa-B ligand) on the osteoblast surface. RANKL binds to RANK on osteoclast precursors, promoting their differentiation into mature, active osteoclasts. Simultaneously, PTH decreases osteoblast production of osteoprotegerin (OPG), the decoy receptor that normally sequesters RANKL and limits osteoclast activation. The combined effect of increased RANKL and decreased OPG shifts the balance strongly toward bone resorption and calcium release.

The kidney effects of PTH are multifaceted and critical for calcium homeostasis. In the distal convoluted tubule, PTH increases calcium reabsorption through upregulation of the TRPV5 calcium channel, conserving calcium that would otherwise be lost in the urine. In the proximal convoluted tubule, PTH decreases phosphate reabsorption by promoting internalization and degradation of the NaPi-IIa and NaPi-IIc sodium-phosphate cotransporters, resulting in phosphaturia that lowers serum phosphorus. Additionally, PTH stimulates the activity of 1-alpha-hydroxylase in the proximal tubule, the enzyme that converts 25-hydroxyvitamin D to the active 1,25-dihydroxyvitamin D (calcitriol). This renal activation of vitamin D represents an indirect but powerful mechanism by which PTH increases serum calcium, because calcitriol then acts on the intestine to enhance calcium absorption.

The intestinal effects of PTH are entirely indirect, mediated through vitamin D activation. PTH has no direct action on intestinal epithelial cells. Rather, by stimulating renal 1-alpha-hydroxylase, PTH increases the production of 1,25-dihydroxyvitamin D, which then acts on duodenal enterocytes to upregulate calcium transport proteins and enhance calcium absorption. This PTH-vitamin D-intestine axis represents the slowest but most sustained mechanism for restoring serum calcium, operating over hours to days as gene transcription for calcium transport proteins is induced. The PTH receptor that mediates these diverse actions is designated PTH1R, a G protein-coupled receptor that signals through both the Gs pathway (increasing cAMP) and the Gq pathway (increasing IP3 and intracellular calcium). PTH1R is expressed on bone and kidney cells and also binds PTH-related peptide (PTHrP), which shares N-terminal homology with PTH.

<image>Panel A: PTH bone effects showing stimulation of osteoclast-mediated bone resorption indirectly via osteoblasts through increased RANKL and decreased osteoprotegerin, releasing calcium and phosphorus into blood. Panel B: PTH kidney effects showing increased calcium reabsorption in distal convoluted tubule via TRPV5, decreased phosphate reabsorption in proximal tubule via downregulation of NaPi-IIa/IIc transporters, and activation of 1-alpha-hydroxylase for vitamin D production. Panel C: PTH indirect intestinal effect showing PTH stimulating renal 1-alpha-hydroxylase, producing active 1,25-dihydroxyvitamin D, which then increases intestinal calcium and phosphate absorption. Panel D: PTH receptor (PTH1R) diagram showing G protein-coupled receptor with Gs (increasing cAMP) and Gq (increasing IP3 and calcium) signaling pathways, located on bone and kidney cells, binding both PTH and PTHrP.</image>

V. Vitamin D Metabolism

Vitamin D is unique among hormones in that it can be synthesized endogenously in the skin as well as obtained from dietary sources. The skin is the primary source of vitamin D under conditions of adequate sun exposure, accounting for approximately 80-90% of the body's supply. In the skin, ultraviolet B (UVB) radiation converts 7-dehydrocholesterol, a cholesterol derivative present in the epidermis, to vitamin D3 (cholecalciferol). Dietary sources provide vitamin D in two forms: vitamin D2 (ergocalciferol), which is derived from plant sources and fungi, and vitamin D3, which is found in fatty fish, egg yolks, and fortified foods. Both forms undergo the same activation steps and have similar biologic activity, though there is some evidence that D3 may be more effective at raising and maintaining serum 25-hydroxyvitamin D levels.

The activation of vitamin D requires two sequential hydroxylation steps occurring in different organs. The first hydroxylation takes place in the liver, where the enzyme 25-hydroxylase converts vitamin D (either D2 or D3) to 25-hydroxyvitamin D, also known as calcidiol or 25(OH)D. This liver step is largely unregulated and substrate-driven, meaning it increases proportionally with vitamin D availability. Calcidiol is the major circulating form of vitamin D and the form measured clinically to assess vitamin D status, because it reflects total body vitamin D stores with a half-life of approximately two to three weeks. The second and critical regulatory hydroxylation occurs in the kidney, where the enzyme 1-alpha-hydroxylase converts 25(OH)D to 1,25-dihydroxyvitamin D, also known as calcitriol or 1,25(OH)2D. Calcitriol is the biologically active hormone that mediates the classic effects of vitamin D on calcium and phosphorus metabolism.

The regulation of 1-alpha-hydroxylase activity determines the rate of active vitamin D production and is tightly controlled by multiple factors. PTH is the primary positive regulator, stimulating 1-alpha-hydroxylase activity and thereby linking calcium homeostasis directly to vitamin D activation. Low serum phosphate independently stimulates 1-alpha-hydroxylase, promoting vitamin D activation to increase phosphate absorption when levels are depleted. Low calcium increases 1-alpha-hydroxylase activity indirectly through its stimulation of PTH release. On the inhibitory side, 1,25(OH)2D itself suppresses 1-alpha-hydroxylase in a classic negative feedback loop, preventing excessive vitamin D activation. FGF23, a phosphaturic hormone produced by osteocytes, also inhibits 1-alpha-hydroxylase activity, serving as an important counter-regulatory signal that links bone-derived signals to vitamin D metabolism.

The inactivation pathway for vitamin D is mediated by 24-hydroxylase, which converts active vitamin D metabolites to inactive forms. This enzyme produces 24,25-dihydroxyvitamin D, which is biologically inactive and represents the initial step in vitamin D catabolism. The regulation of 24-hydroxylase is essentially the mirror image of 1-alpha-hydroxylase: it is upregulated by 1,25(OH)2D (ensuring that when active vitamin D is abundant, degradation is accelerated) and downregulated by PTH (which favors vitamin D activation over degradation). This reciprocal regulation of the activating and inactivating enzymes provides an additional layer of control over the vitamin D system, ensuring that active hormone levels are precisely calibrated to the body's calcium and phosphorus needs.

<image>Panel A: Vitamin D sources showing skin synthesis of vitamin D3 (cholecalciferol) from 7-dehydrocholesterol via UVB light (80-90% under adequate sun exposure) and dietary sources of D2 (ergocalciferol) and D3. Panel B: Two-step activation pathway showing liver 25-hydroxylase producing 25(OH)D (calcidiol, storage form measured clinically) and kidney 1-alpha-hydroxylase producing 1,25(OH)2D (calcitriol, active hormone). Panel C: Regulation of 1-alpha-hydroxylase showing PTH as primary positive regulator, low phosphate and low calcium increasing activity, and negative feedback by 1,25(OH)2D and FGF23 decreasing activity. Panel D: Inactivation by 24-hydroxylase producing inactive 24,25(OH)2D, upregulated by 1,25(OH)2D and downregulated by PTH, serving as the vitamin D degradation pathway.</image>

VI. Vitamin D Actions

The molecular mechanism of vitamin D action follows the paradigm of other steroid and nuclear receptor hormones. Calcitriol (1,25-dihydroxyvitamin D) enters the cell and binds to the vitamin D receptor (VDR), a member of the nuclear receptor superfamily. The VDR then heterodimerizes with the retinoid X receptor (RXR), and this VDR-RXR complex translocates to the nucleus where it binds to specific DNA sequences known as vitamin D response elements (VDREs) in the promoter regions of target genes. Through this mechanism, vitamin D regulates the transcription of genes encoding proteins involved in calcium transport, phosphorus handling, bone metabolism, and numerous other cellular processes. The genomic nature of this signaling pathway explains why the full effects of vitamin D take hours to days to manifest, as they require new protein synthesis.

The intestinal effects of vitamin D represent its most important physiologic role in calcium homeostasis. In the duodenum, which is the primary site of active calcium absorption, calcitriol upregulates the expression of several key calcium transport proteins. These include calbindin, an intracellular calcium-binding protein that shuttles calcium across the enterocyte; TRPV6, an apical calcium channel that mediates calcium entry into the cell from the intestinal lumen; and the plasma membrane calcium-ATPase, which pumps calcium out of the cell across the basolateral membrane into the blood. Vitamin D also increases intestinal phosphate absorption by upregulating the NaPi-IIb sodium-phosphate cotransporter. Together, these effects ensure that adequate calcium and phosphorus are absorbed from the diet to meet the body's needs for bone mineralization and cellular function.

The bone effects of vitamin D are complex and context-dependent. The primary role of vitamin D in bone is to permit normal mineralization by maintaining adequate extracellular concentrations of calcium and phosphate for hydroxyapatite crystal formation. When vitamin D is sufficient, the calcium-phosphorus product in the extracellular fluid is maintained at levels that favor deposition of mineral into the organic bone matrix. However, at high doses, vitamin D can actually increase bone resorption, working synergistically with PTH to mobilize calcium from bone when needed. The consequences of vitamin D deficiency on bone are dramatic and age-dependent: in children, inadequate mineralization of growing bone causes rickets, characterized by soft, deformable bones, bowed legs, and rachitic rosary at the costochondral junctions. In adults, the same failure of mineralization produces osteomalacia, in which newly formed osteoid fails to mineralize, leading to bone pain, muscle weakness, and increased fracture risk.

The renal effects of vitamin D include a modest increase in calcium reabsorption mediated through upregulation of calbindin in the distal tubule, and a minor enhancement of phosphate reabsorption. Beyond its classic effects on mineral metabolism, vitamin D exerts important actions in several other organ systems. In the immune system, vitamin D has immunomodulatory properties that appear to decrease the risk of autoimmune diseases. In skeletal muscle, vitamin D promotes muscle strength and function, and deficiency is associated with increased risk of falls, particularly in elderly populations. In the parathyroid glands, vitamin D directly suppresses PTH gene transcription, completing a negative feedback loop. Vitamin D also demonstrates antiproliferative effects in certain cancer cell lines, and epidemiologic studies have suggested associations between vitamin D deficiency and increased risk of some malignancies, though the clinical significance of this relationship continues to be investigated.

<image>Panel A: Vitamin D receptor mechanism showing nuclear receptor VDR heterodimerizing with RXR, binding vitamin D response elements on DNA, and regulating gene transcription for calcium and phosphate handling proteins. Panel B: Intestinal effects showing increased calcium absorption via upregulated calbindin, TRPV6, and plasma membrane calcium-ATPase in the duodenum, and increased phosphate absorption via NaPi-IIb transporter. Panel C: Bone effects showing vitamin D permitting normal mineralization by maintaining adequate calcium and phosphate for hydroxyapatite formation, with deficiency causing rickets in children and osteomalacia in adults. Panel D: Other vitamin D effects organized by system including immune modulation (decreased autoimmunity), muscle (strength and decreased falls), parathyroid (decreased PTH synthesis), and antiproliferative effects in certain cancers.</image>

VII. Calcitonin and Other Regulators

Calcitonin is a calcium-lowering hormone produced by the parafollicular C cells of the thyroid gland. It is a 32 amino acid peptide with a plasma half-life of approximately 10 minutes, reflecting rapid clearance from the circulation. The primary stimulus for calcitonin secretion is elevated serum calcium, which acts directly on C cells to trigger hormone release. The principal physiologic action of calcitonin is to inhibit osteoclast activity directly, thereby decreasing bone resorption and lowering serum calcium. Calcitonin also produces a modest decrease in serum phosphorus through reduced bone resorption. However, the physiologic importance of calcitonin in adult humans appears to be minimal, as patients who have undergone total thyroidectomy (and thus lack calcitonin entirely) do not develop significant abnormalities in calcium homeostasis. Calcitonin is therefore considered to be more important pharmacologically than physiologically, as it can be administered therapeutically for the acute management of hypercalcemia and for the treatment of Paget disease of bone, where its osteoclast-inhibiting properties provide clinical benefit.

Fibroblast growth factor 23 (FGF23) has emerged as a critically important regulator of phosphorus and vitamin D metabolism. FGF23 is produced by osteocytes, the most abundant cells in mature bone, establishing bone as an endocrine organ that communicates mineral status to the kidneys. The primary stimuli for FGF23 secretion are elevated serum phosphate and elevated 1,25-dihydroxyvitamin D. FGF23 acts on the kidney to decrease renal phosphate reabsorption by downregulating the NaPi-IIa and NaPi-IIc sodium-phosphate cotransporters in the proximal tubule, thereby promoting phosphaturia. Simultaneously, FGF23 inhibits renal 1-alpha-hydroxylase, decreasing the production of active vitamin D. The net result is a reduction in serum phosphorus (through increased urinary losses) and a reduction in serum vitamin D (through decreased activation). Disorders of FGF23 excess cause clinically significant hypophosphatemia, as seen in X-linked hypophosphatemia (XLH), the most common inherited form of rickets, and in tumor-induced osteomalacia (TIO), a paraneoplastic syndrome in which mesenchymal tumors secrete excessive FGF23. In both conditions, chronic hypophosphatemia leads to impaired bone mineralization.

PTH-related peptide (PTHrP) is a protein that shares significant N-terminal homology with PTH and binds the same PTH1R receptor, producing similar biologic effects on calcium and phosphorus metabolism. Under normal physiologic conditions, PTHrP functions as a local paracrine and autocrine factor rather than a circulating hormone. It plays important roles in cartilage development, where it regulates chondrocyte proliferation and differentiation; in breast tissue, where it is involved in mammary gland development and calcium mobilization during lactation; and in fetal development, where it helps regulate placental calcium transport. The pathologic significance of PTHrP lies in its role as the primary mediator of humoral hypercalcemia of malignancy, the most common cause of hypercalcemia in hospitalized patients. Certain malignancies, particularly squamous cell carcinomas of the lung, renal cell carcinoma, and breast cancer, produce excessive PTHrP that enters the systemic circulation and mimics the effects of PTH, causing increased bone resorption, increased renal calcium reabsorption, and severe hypercalcemia.

<image>Panel A: Calcitonin from thyroid parafollicular C cells showing 32 amino acid peptide structure, stimulated by high serum calcium, inhibiting osteoclasts directly to decrease bone resorption, with note that physiologic role is minimal in adults. Panel B: FGF23 from osteocytes showing stimulation by high phosphate and high 1,25(OH)2D, actions decreasing renal phosphate reabsorption and decreasing 1-alpha-hydroxylase activity, resulting in lower serum phosphate and lower vitamin D levels. Panel C: PTHrP showing N-terminal homology with PTH, binding the same PTH1R receptor, normal paracrine function in cartilage, breast, and fetal tissues, and pathologic role in humoral hypercalcemia of malignancy. Panel D: FGF23 disorders showing excess FGF23 causing hypophosphatemia in X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), with clinical consequences of impaired bone mineralization.</image>

VIII. Bone Physiology

Bone is a dynamic, living tissue composed of both organic and inorganic elements that together provide mechanical strength, protect vital organs, and serve as the body's mineral reservoir. The mineral component, consisting primarily of hydroxyapatite crystals, accounts for 65-70% of bone by weight and confers the rigidity and compressive strength that allow the skeleton to bear mechanical loads. The organic matrix, predominantly type I collagen fibers, constitutes 20-25% of bone and provides tensile strength and flexibility, preventing the brittle fractures that would occur if bone were purely mineral. Water accounts for 5-10% of bone mass, and cellular elements make up less than 5%. This composite structure, analogous to reinforced concrete where collagen serves as the rebar and mineral as the cement, gives bone its remarkable combination of strength and resilience.

The three principal bone cell types each have distinct developmental origins and functions that together maintain skeletal integrity. Osteoblasts are the bone-forming cells, derived from mesenchymal stem cells in the bone marrow. They synthesize and secrete the organic matrix (osteoid) and regulate its subsequent mineralization. As osteoblasts become embedded within the matrix they have produced, they differentiate into osteocytes, the most abundant cell type in mature bone. Osteocytes reside within lacunae connected by an extensive canalicular network, and they function as mechanosensors, detecting mechanical loads and microdamage and initiating appropriate remodeling responses. Osteocytes also play a central role in mineral regulation, producing FGF23 to control phosphorus homeostasis and sclerostin to modulate bone formation. Osteoclasts are the bone-resorbing cells, derived from the hematopoietic monocyte-macrophage lineage. These large, multinucleated cells attach to the bone surface and create a sealed resorption lacuna (Howship lacuna) where they secrete hydrochloric acid to dissolve the mineral phase and proteolytic enzymes (particularly cathepsin K) to degrade the organic matrix.

Bone remodeling is a continuous, tightly coupled process that replaces old or damaged bone with new bone throughout life. The remodeling cycle proceeds through five sequential phases and takes approximately 4-6 months to complete. The activation phase begins when osteocytes detect microdamage or respond to hormonal signals, recruiting osteoclast precursors to the remodeling site. During the resorption phase, mature osteoclasts excavate a resorption cavity, a process lasting approximately 3 weeks. The reversal phase represents a transition period during which coupling factors released from the resorbed bone matrix and from osteoclasts themselves recruit and activate osteoblast precursors. The formation phase follows, during which osteoblasts fill the resorption cavity with new osteoid that subsequently mineralizes; this phase lasts approximately 3 months, reflecting the slower pace of bone formation compared to resorption. Finally, the quiescence phase returns the bone surface to a resting state until the next remodeling cycle is initiated.

The RANK/RANKL/OPG signaling system is the master regulatory mechanism controlling osteoclast differentiation and activity, and therefore bone resorption. RANKL (receptor activator of nuclear factor kappa-B ligand) is a membrane-bound and soluble cytokine produced by osteoblasts and bone marrow stromal cells. It binds to RANK (receptor activator of nuclear factor kappa-B), which is expressed on osteoclast precursors and mature osteoclasts. RANKL-RANK binding is the essential signal for osteoclast precursor differentiation, fusion into multinucleated osteoclasts, activation of mature osteoclasts, and osteoclast survival. Osteoprotegerin (OPG) is a soluble decoy receptor also produced by osteoblasts that competes with RANK for RANKL binding, effectively neutralizing RANKL and inhibiting osteoclast formation and activity. The balance between RANKL and OPG, expressed as the RANKL-to-OPG ratio, determines the net rate of bone resorption. Conditions that increase this ratio (such as estrogen deficiency in menopause, PTH excess, or inflammatory cytokine production) promote bone loss, while conditions that decrease it (such as estrogen replacement) favor bone preservation. This pathway is the target of the therapeutic agent denosumab, a monoclonal antibody against RANKL used in the treatment of osteoporosis.

<image>Panel A: Bone composition showing mineral hydroxyapatite (65-70%), organic matrix predominantly type I collagen (20-25%), water (5-10%), and cells (less than 5%) with structural organization diagram. Panel B: Bone cell types showing osteoblasts (mesenchymal origin, bone formation), osteocytes (embedded osteoblasts, mechanosensing and mineral regulation), and osteoclasts (hematopoietic monocyte/macrophage lineage, bone resorption). Panel C: Bone remodeling cycle showing sequential phases of activation (osteocyte signals, microdamage detection), resorption (osteoclasts, approximately 3 weeks), reversal (transition with coupling factors), formation (osteoblasts lay new bone, approximately 3 months), and quiescence with total cycle of 4-6 months. Panel D: RANK/RANKL/OPG system showing RANKL from osteoblasts activating RANK on osteoclast precursors to stimulate resorption, and osteoprotegerin (OPG) from osteoblasts acting as decoy receptor to inhibit RANKL, with the RANKL-to-OPG ratio determining net resorption activity.</image>

IX. Phosphorus Homeostasis

Phosphorus is the second most abundant mineral in the body after calcium, and its distribution across compartments reflects its diverse structural and metabolic roles. The vast majority of body phosphorus, approximately 85%, resides in bone as part of hydroxyapatite crystals, where it serves a structural function alongside calcium. Soft tissues contain approximately 14% of total body phosphorus, where it participates in energy metabolism, nucleic acid structure, and cell signaling. Only 1% of body phosphorus is found in the extracellular fluid, where the normal serum phosphorus concentration is maintained between 2.5 and 4.5 mg/dL. Unlike calcium, a relatively large proportion of plasma phosphorus is freely filtered at the glomerulus: approximately 55% circulates in the ionized form, 35% is complexed with cations, and only 10% is protein-bound.

The hormonal regulation of serum phosphorus involves the coordinated actions of three major hormones, each with distinct effects. PTH decreases serum phosphorus by promoting renal phosphate excretion, a phosphaturic effect that is critical for preventing the calcium-phosphorus product from rising excessively when PTH simultaneously raises serum calcium. Vitamin D (1,25-dihydroxyvitamin D) increases serum phosphorus by enhancing intestinal phosphate absorption, an effect that occurs alongside its more commonly emphasized role in calcium absorption. FGF23 decreases serum phosphorus by promoting renal phosphate excretion and by suppressing vitamin D activation, thereby reducing intestinal phosphate absorption as well. The interplay among these three hormones ensures that phosphorus levels are maintained within the physiologic range despite wide variations in dietary phosphorus intake.

The renal handling of phosphorus is the principal mechanism for minute-to-minute regulation of serum phosphorus levels. Approximately 80% of filtered phosphate is reabsorbed in the proximal convoluted tubule, mediated by the NaPi-IIa and NaPi-IIc sodium-phosphate cotransporters on the apical membrane of proximal tubular cells. Both PTH and FGF23 decrease the expression of these transporters on the cell surface by promoting their internalization and lysosomal degradation, resulting in increased urinary phosphate excretion. The remaining filtered phosphate is largely excreted in the urine, making the kidney the dominant regulator of phosphorus balance. In chronic kidney disease, the progressive loss of nephrons impairs phosphate excretion, leading to hyperphosphatemia that drives secondary hyperparathyroidism and contributes to the mineral bone disease of renal failure.

Phosphorus serves numerous essential functions throughout the body that extend far beyond its structural role in bone. As a component of hydroxyapatite, with the chemical formula Ca10(PO4)6(OH)2, phosphorus is indispensable for bone mineralization. Phosphorus is central to energy metabolism as a component of ATP and ADP, the universal energy currency of cells. It forms the sugar-phosphate backbone of DNA and RNA, making it essential for genetic information storage and transfer. Phosphorylation of proteins by kinases is one of the most important mechanisms of intracellular signal transduction, regulating enzyme activity, gene expression, and cell behavior. Additionally, phosphate serves as an important urinary buffer, accepting hydrogen ions in the renal tubule (forming titratable acid) and thereby contributing to the kidney's role in maintaining acid-base balance. This diverse array of functions explains why both hypophosphatemia and hyperphosphatemia can produce widespread and serious clinical consequences.

<image>Panel A: Phosphorus distribution showing 85% in bone, 14% in soft tissue, and 1% extracellular with normal serum phosphorus of 2.5-4.5 mg/dL and plasma forms (55% ionized, 10% protein-bound, 35% complexed). Panel B: Hormonal regulation of phosphorus showing PTH decreasing serum phosphorus (increased renal excretion), vitamin D increasing serum phosphorus (increased intestinal absorption), and FGF23 decreasing serum phosphorus (increased renal excretion). Panel C: Renal phosphorus handling showing 80% reabsorption in proximal convoluted tubule via NaPi-IIa and NaPi-IIc transporters, with PTH and FGF23 both decreasing transporter expression to increase phosphate excretion. Panel D: Phosphorus functions including bone mineralization as hydroxyapatite, energy metabolism (ATP, ADP), nucleic acid backbone (DNA, RNA), cell signaling via phosphorylation cascades, and urinary hydrogen ion buffering.</image>

X. Integrated Calcium-Phosphorus Regulation

The body's response to hypocalcemia illustrates the beautifully coordinated interplay among the calcium-regulating hormones and their target organs. When serum ionized calcium falls, the calcium-sensing receptor on parathyroid chief cells detects the change and PTH secretion increases within seconds to minutes. The released PTH acts on multiple target organs simultaneously. In bone, PTH stimulates osteoclast-mediated resorption through the RANKL pathway, rapidly releasing calcium and phosphorus from the skeletal reservoir. In the kidney, PTH increases calcium reabsorption in the distal convoluted tubule, conserving calcium that would otherwise be lost in the urine. Also in the kidney, PTH stimulates 1-alpha-hydroxylase, increasing the production of active 1,25-dihydroxyvitamin D. Over the subsequent hours to days, the increased calcitriol acts on the intestine to upregulate calcium absorption, providing additional calcium from the diet. Through these coordinated mechanisms, serum calcium is restored to normal.

The response to hypercalcemia is essentially the mirror image of the hypocalcemic response, utilizing the same hormonal axes in the opposite direction. When serum ionized calcium rises above the normal range, the calcium-sensing receptor is activated, suppressing PTH release from the parathyroid glands. The resulting decrease in PTH leads to reduced bone resorption, as the stimulus for RANKL expression on osteoblasts diminishes. In the kidney, decreased PTH leads to decreased calcium reabsorption, allowing more calcium to be excreted in the urine. The reduction in PTH also decreases 1-alpha-hydroxylase activity, lowering the production of active vitamin D. The consequent decrease in calcitriol levels reduces intestinal calcium absorption. Through these parallel mechanisms, the excess calcium is eliminated and serum calcium returns to the normal range. The symmetry of these two responses demonstrates the precision of the calcium homeostatic system.

The calcium-phosphorus product is an important clinical concept, particularly in the management of patients with chronic kidney disease. The product of the serum calcium concentration multiplied by the serum phosphorus concentration is normally maintained below 55 mg-squared per dL-squared. When this product exceeds that threshold, there is an increased risk of soft tissue calcification, in which calcium phosphate crystals deposit in blood vessels, heart valves, periarticular tissues, and other soft tissues. This metastatic calcification is a major contributor to cardiovascular morbidity and mortality in patients with end-stage renal disease. PTH plays an important role in keeping the calcium-phosphorus product stable under normal conditions, because its simultaneous effects of raising serum calcium and lowering serum phosphorus tend to offset each other with respect to the product.

The overall hormonal regulation of calcium and phosphorus metabolism involves four major hormones, each with distinct effects and stimuli. PTH raises serum calcium and lowers serum phosphorus, and its primary stimulus is low serum calcium detected through the CaSR. Active vitamin D (1,25-dihydroxyvitamin D) raises both serum calcium and serum phosphorus through enhanced intestinal absorption, and its production is stimulated primarily by PTH and by low phosphate levels. Calcitonin lowers both serum calcium and serum phosphorus, primarily through direct inhibition of osteoclast-mediated bone resorption, and is stimulated by high serum calcium. FGF23 indirectly lowers serum calcium (by decreasing vitamin D production) and directly lowers serum phosphorus (by promoting renal phosphate excretion), and is stimulated by high phosphate and high vitamin D levels. The integration of these four hormonal signals ensures that calcium and phosphorus concentrations are maintained within their respective physiologic ranges despite constant challenges from dietary intake, bone turnover, and renal excretion.

<image>Panel A: Response to hypocalcemia showing sequential steps from low calcium sensed by CaSR, to increased PTH release, to PTH effects on bone resorption, renal calcium reabsorption, and vitamin D activation leading to increased intestinal absorption until serum calcium normalizes. Panel B: Response to hypercalcemia showing high calcium sensed by CaSR, decreased PTH release, decreased bone resorption, decreased renal calcium reabsorption, decreased vitamin D production, and decreased intestinal absorption until calcium normalizes. Panel C: Calcium-phosphorus product concept showing normal product less than 55 mg-squared per dL-squared, elevated product risking soft tissue calcification, and PTH's role in maintaining stable product by simultaneously increasing calcium and decreasing phosphorus. Panel D: Hormone summary table showing PTH (increases calcium, decreases phosphorus, stimulated by low calcium), 1,25(OH)2D (increases both calcium and phosphorus, stimulated by PTH and low phosphate), calcitonin (decreases both, stimulated by high calcium), and FGF23 (indirectly decreases calcium and directly decreases phosphorus, stimulated by high phosphate and high vitamin D).</image>

Summary

• Calcium: 99% in bone; ionized fraction is physiologically active
• PTH: Released with low Ca²⁺; ↑ bone resorption, ↑ renal Ca²⁺, ↑ vitamin D activation
• Vitamin D: Activated in liver then kidney; ↑ intestinal Ca²⁺ and PO₄ absorption
• Calcitonin: From C cells; ↓ bone resorption; minor physiologic role
• FGF23: From osteocytes; ↓ serum phosphate; ↓ vitamin D
• Bone remodeling: Osteoclasts resorb, osteoblasts form; RANKL/OPG balance
• Integrated response: Hypocalcemia → ↑ PTH → restore calcium via bone, kidney, gut

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown